113 related articles for article (PubMed ID: 24287063)
1. First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms.
Stein H; Diehl V
Hematol Oncol Clin North Am; 2014 Feb; 28(1):1-11. PubMed ID: 24287063
[TBL] [Abstract][Full Text] [Related]
2. CD30 as a therapeutic target for lymphoma.
Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
[TBL] [Abstract][Full Text] [Related]
3. CD30 in normal and neoplastic cells.
Chiarle R; Podda A; Prolla G; Gong J; Thorbecke GJ; Inghirami G
Clin Immunol; 1999 Feb; 90(2):157-64. PubMed ID: 10080826
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
Pohl C; Sieber M; Diehl V; Pfreundschuh M
Anticancer Res; 1991; 11(3):1115-24. PubMed ID: 1653553
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
[TBL] [Abstract][Full Text] [Related]
6. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells.
Horie R; Watanabe T; Morishita Y; Ito K; Ishida T; Kanegae Y; Saito I; Higashihara M; Mori S; Kadin ME; Watanabe T
Oncogene; 2002 Apr; 21(16):2493-503. PubMed ID: 11971184
[TBL] [Abstract][Full Text] [Related]
7. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
8. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells.
Watanabe M; Ogawa Y; Ito K; Higashihara M; Kadin ME; Abraham LJ; Watanabe T; Horie R
Am J Pathol; 2003 Aug; 163(2):633-41. PubMed ID: 12875982
[TBL] [Abstract][Full Text] [Related]
9. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
10. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
11. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
12. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
[TBL] [Abstract][Full Text] [Related]
13. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
14. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Guo F; Sun A; Wang W; He J; Hou J; Zhou P; Chen Z
Mol Immunol; 2009 Aug; 46(13):2441-8. PubMed ID: 19540595
[TBL] [Abstract][Full Text] [Related]
15. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
[TBL] [Abstract][Full Text] [Related]
16. Identification of an Mr 70,000 antigen associated with Reed-Sternberg cells and interdigitating reticulum cells.
Hsu PL; Hsu SM
Cancer Res; 1990 Jan; 50(2):350-7. PubMed ID: 2153049
[TBL] [Abstract][Full Text] [Related]
17. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
[TBL] [Abstract][Full Text] [Related]
18. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
[TBL] [Abstract][Full Text] [Related]
19. CD30: expression and function in health and disease.
Horie R; Watanabe T
Semin Immunol; 1998 Dec; 10(6):457-70. PubMed ID: 9826579
[TBL] [Abstract][Full Text] [Related]
20. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies.
Dietlein M; Börner SM; Fischer T; Hansen H; Schnell R; Zimmermanns B; Tawadros S; Engert A; Staak O; Pogge von Strandmann E; Kobe C; Schicha H; Schomäcker K
Nuklearmedizin; 2010; 49(3):97-105. PubMed ID: 20126826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
